May 8th 2024
Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.
Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC
March 1st 2024Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.
Lapatinib Does Not Improve CRT Outcomes in Non-HPV Head and Neck Carcinoma
October 27th 2023Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.
Camrelizumab Yields ‘Impressive’ Activity in Head & Neck Cancer Subtype
March 7th 2023Camrelizumab plus apatinib demonstrates impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.
Adjuvant Capecitabine Plus Concurrent CRT Yields FFS Benefit in Locoregionally Advanced LA-NPC
November 20th 2022Adjuvant capecitabine following concurrent chemoradiotherapy yielded higher failure-free survival rates compared with chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Pembrolizumab Plus Chemotherapy Demonstrates Continued Benefit in Recurrent/Metastatic HNSCC
October 21st 2022Findings from the phase 3 KEYNOTE-048 study indicated that long-lasting improved survival benefit can be achieved with pembrolizumab plus chemotherapy compared with cetuximab and chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
FDA Grants Fast Track Designation to CUE-101 ± Pembrolizumab for HPV16+ Advanced HNSCC
October 4th 2022CUE-101 alone or in combination with pembrolizumab was granted fast track designation by the FDA for patients with human papillomavirus 16–positive recurrent/metastatic head and neck squamous cell carcinoma.
Triplet Induction Chemotherapy Improves FFS in Nasopharyngeal Carcinoma Vs Doublet Regimen
September 15th 2022Patients with stage IVA to IVB nasopharyngeal carcinoma experienced an improvement in failure-free survival following treatment with paclitaxel, cisplatin, and capecitabine for 2 cycles vs 2 cycles of cisplatin and fluorouracil.